› 4tt7

X-ray diffraction
2.1Å resolution

Crystal structure of human ALK with a covalent modification

Released:
DOI: 10.2210/pdb4tt7/pdb
PDB entry 4tt7 coloured by chain, front view.
PDB entry 4tt7 coloured by chain, side view.
PDB entry 4tt7 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
Parker AR, Petluru PN, Nienaber VL, Zhao M, Ayala PY, Badger J, Chie-Leon B, Sridhar V, Logan C, Kochat H, Hausheer FH
OpenAccess logo Onco Targets Ther 8 375-83 (2015)
PMID: 25678804

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-193961 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
ALK tyrosine kinase receptor Chain: A
Molecule details ›
Chain: A
Length: 325 amino acids
Theoretical weight: 36.77 KDa
Source organism: Homo sapiens
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: Q9UM73 (Residues: 1095-1410; Coverage: 20%)
Gene name: ALK
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

2 bound ligands:
Ligand COM 2 x COM
Ligand EDO 3 x EDO
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: ALS BEAMLINE 5.0.1
Spacegroup: P212121
Unit cell:
a: 51.535Å b: 57.157Å c: 104.216Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.195 0.192 0.244
Expression system: Spodoptera frugiperda

Quick links

Citations

1 review citation

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics-A Review.
Stankovic et al. (2020)
1 other article

3 mentions without citation

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787.
Parker et al. (2015)
2 more